Supplement guide · Mood, sleep and cognition

Saffron: Mood, Anxiety and Sleep

📄 26 PubMed citations

Saffron extract, made from the stigmas of the Crocus sativus flower, is sold for low mood and poor sleep. Pooled trials favour it on self-rated symptoms, but reviewers keep flagging publication bias, and many products do not match their labels.

🔬 Saffron is the dried stigma of the Crocus sativus flower, and it is now sold as a mood and sleep extract; the trials cited here used 15 to 30 mg a day, apart from one week-long safety test of 200 and 400 mg. When we sorted the PubMed record by study design, we found many small placebo-controlled and head-to-head trials, many of the early ones run in Iran, and a newer set of trials of branded extracts such as affron, several funded by the extract makers. Pooled results favour saffron on self-rated depression and anxiety, yet three reviews raise publication bias or a lack of trials from outside Iran, and a 6-week French trial in 51 healthy adults found no effect on its main outcome. This page lists each finding with its study type and dose, flags industry sponsorship where the PubMed record states it, then covers safety and product quality.
34
Randomized trials pooled in a 2026 GRADE-rated meta-analysis
202
Adults with low mood in the largest saffron trial to date
65%
Saffron supplements, of 17 tested, whose contents did not match the label
Open book with reading glasses resting on a dark quilted bed beside folded white towels
Photo: nenadstojkovicart · CC BY · source

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

What Is Saffron and How Might It Work?

🌸
A spice from a flower

Saffron is the dried stigma of Crocus sativus. Its main bioactive components are crocins and safranal (affron mood trial, PMID 28735826), and a lab analysis of reference samples (dried saffron stigmas and the affron extract) found up to 17 crocins and crocetins plus picrocrocin and safranal (saffron supplement quality study, PMID 38002129).

🧪
Proposed brain targets

A 2022 review of 414 research papers lists monoamine reuptake inhibition, NMDA receptor antagonism and GABA-α agonism as the main proposed antidepressant mechanisms, and says the mechanism, drug interactions and safety are not fully understood (saffron compounds review, PMID 36678554).

⏱️
The stress-hormone question

Results conflict. A 6-week French trial found no effect on inflammatory markers or HPA-axis (stress system) reactivity (subclinical mood trial, PMID 41047129). An 8-week Indian trial funded by its extract maker reported lower serum cortisol at days 28 and 56 (UO SAF 02 trial, PMID 42465135).

🦠
A gut-bacteria signal

In a 52-person pilot of older adults with sleep complaints, 30 mg a day for four weeks improved self-rated and EEG-tracked sleep. In a subgroup of 26 whose gut bacteria were analysed, saffron raised several bacteria, including Faecalibacterium, Prevotella and Oscillibacter, with the authors noting a rise in short-chain-fatty-acid producers, and some shifts correlated with sleep measures (older-adult sleep pilot, PMID 40762630). This shows a correlation, not a cause.

What the Data Shows

Clinically meaningful mood gain, 12 weeks
202 adults with low mood on 28 mg a day: 72.3% reached a 7-point or larger drop on the DASS-21 depression scale vs 54.3% on placebo (P = 0.010); industry-sponsored (affron low-mood trial; PMID 40414301)
72% vs 54%
Same bar, women aged 50 to 70
86 women with low mood and poor sleep on 28 mg a day for 12 weeks: 48.8% vs 25.6% on placebo (p = 0.026); industry-sponsored (affron women trial; PMID 42389708)
49% vs 26%
Add-on to an antidepressant, 8 weeks
160 adults with persistent depression (139 analysed): clinician-rated MADRS fell 41% on saffron vs 21% on placebo (p = 0.001), but the self-rated MADRS-S fell 27% vs 26% (p = 0.831) (affron add-on trial; PMID 31475623)
41% vs 21%
Healthy adults with mild symptoms, 6 weeks
51 adults: no effect on the combined depression, anxiety and fatigue score or on any single symptom; only a self-rated mental-health score improved (subclinical mood trial; PMID 41047129)
No effect

Daily Dosing Schedule

TimeCompounds
Low mood, anxiety, sleep (affron)28 mg a day, usually split as 14 mg twice daily, for 4 to 12 weeks (sleep trial, PMID 32056539; teen trial, PMID 29510352; low-mood trial, PMID 40414301). In one 4-week trial, 22 mg a day had no effect while 28 mg did (PMID 28735826).
Depression trials against SSRIs30 mg a day of saffron in 6-week comparisons with fluoxetine 20 mg (PMID 15707766) and citalopram 40 mg (PMID 27701683).
Moderate insomnia20 or 30 mg a day of a different extract (Safr'Inside) for 4 weeks (insomnia trial, PMID 40698027).
Alzheimer's disease trials30 mg a day for 22 weeks against donepezil, given as 15 mg twice daily (PMID 19838862), or for 12 months against memantine (PMID 25163440).
Short safety test, higher doses200 or 400 mg tablets for 7 days in 20 healthy volunteers (plus 10 on placebo); 400 mg lowered standing systolic blood pressure (safety study, PMID 18693099).

Key Takeaways

What We Know
  • A 2026 meta-analysis of 34 randomized trials (1,769 people) found saffron lowered self-rated depression (BDI, 14 trials) by 4.39 points and self-rated anxiety (BAI, 6 trials) by 5.06 points, with moderate certainty (PMID 41693488).
  • In the largest trial, 202 adults with low mood took 28 mg a day or placebo for 12 weeks; 72.3% on saffron vs 54.3% on placebo reached a clinically meaningful drop in depression score (PMID 40414301).
  • In small 6-week trials, 30 mg of saffron a day showed no significant difference from fluoxetine in 40 outpatients with mild to moderate depression (PMID 15707766) or from citalopram in 66 patients with depression and anxious distress (PMID 27701683).
  • Three placebo-controlled sleep trials point the same way: 14 mg twice daily improved insomnia scores in 63 adults (PMID 32056539), 20 or 30 mg cut insomnia symptoms in 165 adults (PMID 40698027), and 30 mg shortened tracker-measured sleep onset in 52 older adults (PMID 40762630). The first trial was funded by Pharmactive (PMID 32056539) and the second reports industry support from Activ'Inside (PMID 40698027).
  • A 2020 meta-analysis of 12 studies found no significant difference in adverse effects between saffron and placebo, or between saffron and antidepressants (PMID 32221179).
  • Product quality is uneven: of 17 saffron supplements analysed, 65% had contents that did not match the label, and some had undeclared additives or plant material other than saffron; two of its authors worked for the extract company Pharmactive (PMID 38002129).
What We Don't Know
  • Whether clinicians would see the change. The 2026 meta-analysis found no significant effect on the clinician-rated HDRS or HARS scales (PMID 41693488), while the add-on trial found the reverse: a clinician-rated gain and no self-rated gain (PMID 31475623).
  • How much of the pooled effect is real. A 2019 meta-analysis found evidence of publication bias and a lack of regional diversity (PMID 31135916), a 2021 meta-review said the saffron meta-analyses may have significant publication bias (PMID 33596697), and a 2013 meta-analysis asked for larger trials run outside Iran (PMID 24299602).
  • Whether it helps people with only mild symptoms. A 6-week trial in 51 healthy adults found no effect on its main outcome (PMID 41047129), and a 22 mg daily dose did nothing in a 4-week trial of 128 adults (PMID 28735826).
  • How independent the newer trials are. The largest trial lists two employees of the study sponsor, Pharmactive Biotech Products, as authors (PMID 40414301), and the funder helped design the women's trial (PMID 42389708).
  • Whether it is safe in pregnancy. A 2026 review links higher doses or occupational exposure to uterine stimulation and a higher miscarriage risk (PMID 42186868).
  • Long-term safety for mood use. The mood trials cited here ran 12 weeks at most (PMID 40414301, PMID 42389708); the one 12-month trial was in Alzheimer's disease and had no placebo group (PMID 25163440).

Frequently Asked Questions

Does saffron work for depression?

For self-rated symptoms, the pooled evidence says it may help. A 2026 meta-analysis of 34 trials found lower self-rated depression (BDI) scores, but no significant effect on the clinician-rated Hamilton scale (2026 GRADE meta-analysis, PMID 41693488). The 2022 WFSBP and CANMAT taskforce gave saffron a provisional recommendation for unipolar depression (WFSBP guideline, PMID 35311615). Reviewers have also flagged publication bias (2019 meta-analysis, PMID 31135916).

Does saffron help with anxiety?

Self-rated anxiety fell in pooled trials. Across six trials with 339 people, saffron lowered Beck Anxiety Inventory scores by 5.06 points, while the clinician-rated HARS showed no significant change (2026 GRADE meta-analysis, PMID 41693488). In 80 teenagers aged 12 to 16, 14 mg twice daily for 8 weeks improved self-reported anxiety, but parent reports were inconsistent (affron teen trial, PMID 29510352).

Does saffron help you sleep?

Three placebo-controlled trials report better sleep over four weeks. In 63 adults with poor sleep, 14 mg twice daily improved Insomnia Severity Index scores (affron sleep trial, PMID 32056539). In 165 adults with moderate insomnia, 20 or 30 mg a day reduced insomnia symptoms and stress (insomnia trial, PMID 40698027). In 52 older adults, 30 mg shortened sleep onset on an EEG tracker (older-adult sleep pilot, PMID 40762630).

How much saffron do studies use?

The trials cited here mostly gave 28 to 30 mg of extract a day. The affron trials used 28 mg (low-mood trial, PMID 40414301), often split as 14 mg twice daily (sleep trial, PMID 32056539; teen trial, PMID 29510352), and the head-to-head depression trials used 30 mg (fluoxetine comparison, PMID 15707766). In one 4-week trial, 28 mg a day improved mood scores and 22 mg a day did not (affron mood trial, PMID 28735826).

Is saffron safe to take?

At trial doses it was well tolerated in the studies here. A 2020 meta-analysis found no difference in adverse effects vs placebo (2020 meta-analysis, PMID 32221179). In a one-week test of 200 and 400 mg tablets, the 400 mg dose lowered standing systolic blood pressure, and some blood values shifted within normal ranges (safety study, PMID 18693099). A 2026 review links higher doses to miscarriage risk (pregnancy review, PMID 42186868).

Can saffron be taken with an antidepressant?

Some trials enrolled people already on one, under study supervision. In a trial of 160 adults on an antidepressant (139 analysed), 14 mg twice daily for 8 weeks improved clinician-rated depression scores (affron add-on trial, PMID 31475623). In men and women on fluoxetine, 30 mg a day for 4 weeks improved some sexual side effects, with side-effect rates similar to placebo (men's trial, PMID 22552758; women's trial, PMID 23280545). Ask your prescriber before combining them.

Peer-Reviewed References

Source 1
Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials
Nutr Neurosci · 2026
PMID: 41693488
Source 2
An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial
J Nutr · 2025
PMID: 40414301
Source 3
Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study
Am J Clin Nutr · 2025
PMID: 41047129
Source 4
affron(®) a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial
Complement Ther Med · 2017
PMID: 28735826
Source 5
affron(®), a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study
J Affect Disord · 2018
PMID: 29510352
Source 6
The effects of a saffron extract (Affron®) on mood, sleep, self-esteem, and exploratory measures of physical appearance in women aged 50 to 70 years experiencing low mood and poor sleep: a randomised, double-blind, placebo-controlled trial
Front Nutr · 2026
PMID: 42389708
Source 7
Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study
J Psychopharmacol · 2019
PMID: 31475623
Source 8
Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial
J Ethnopharmacol · 2005
PMID: 15707766
Source 9
Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial
Pharmacopsychiatry · 2017
PMID: 27701683
Source 10
Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis
Nutr Rev · 2019
PMID: 31135916
Source 11
Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés
Can J Psychiatry · 2021
PMID: 33596697
Source 12
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce
World J Biol Psychiatry · 2022
PMID: 35311615
Source 13
Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials
J Integr Med · 2013
PMID: 24299602
Source 14
Safety and Efficacy of Saffron (Crocus sativus L.) for Treating Mild to Moderate Depression: A Systematic Review and Meta-analysis
J Nerv Ment Dis · 2020
PMID: 32221179
Source 15
Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial
J Clin Sleep Med · 2020
PMID: 32056539
Source 16
Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial
Sleep Med X · 2025
PMID: 40698027
Source 17
A standardised saffron extract improves subjective and objective sleep quality in healthy older adults with sleep complaints: results from the gut-sleep-brain axis randomised, double-blind, placebo-controlled pilot study
Food Funct · 2025
PMID: 40762630
Source 18
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease
Psychopharmacology (Berl) · 2010
PMID: 19838862
Source 19
Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial
Hum Psychopharmacol · 2014
PMID: 25163440
Source 20
Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial
Psychopharmacology (Berl) · 2012
PMID: 22552758
Source 21
Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study
Hum Psychopharmacol · 2013
PMID: 23280545
Source 22
Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers
Phytomedicine · 2008
PMID: 18693099
Source 23
Saffron and Pregnancy: Cultural Practices, Beliefs, and Safety Evidence: An Integrative Review
J Evid Based Integr Med · 2026
PMID: 42186868
Source 24
A Combined Gas and Liquid Chromatographic Approach for Quality Evaluation of Saffron-Based Food Supplements
Foods · 2023
PMID: 38002129
Source 25
Current Knowledge of the Antidepressant Activity of Chemical Compounds from Crocus sativus L
Pharmaceuticals (Basel) · 2022
PMID: 36678554
Source 26
Standardized Saffron Extract Formulation for Low Mood and Subclinical Depressive Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial
Cureus · 2026
PMID: 42465135
Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →
Disclaimer

Educational purposes only. Not medical advice.

Saffron extract is sold in the US as a dietary supplement, not an FDA-approved drug. Talk to a clinician before using it if you are pregnant, take prescription medicines such as antidepressants, or are being treated for depression or any other condition.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.